Posted by Michael Wonder on 11 Nov 2021
US FDA accepts supplemental new drug application and grants priority review for Jardiance for adults with heart failure independent of left ventricular ejection fraction
11 November 2021 - If approved, Jardiance would be the first clinically proven treatment for adults across the full spectrum of heart failure regardless of ejection fraction.
The U.S. FDA has accepted a supplemental new drug application and granted priority review for Jardiance (empagliflozin) 10 mg, which is being investigated as a potential new treatment to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure independent of left ventricular ejection fraction, Boehringer Ingelheim and Eli Lilly announced.
